Latest Headlines

Latest Headlines

Sanofi Pasteur nabs Menactra expansion in Canada

Health Canada gave the nod to Sanofi Pasteur Canada to expand the indication for Menactra to infants 9 months of age.

Novartis nabs EU committee backing for meningitis B vaccine

Novartis ($NVS) hit a key turning point with its vaccines division when a European Union committee backed the company's Bexsero meningitis shot.

Novartis grabs EU committee support for first meningitis B vaccine

Novartis has scored a key endorsement for one of the brightest stars from its vaccines division. The European Union's Committee for Medicinal Products for Human Use (CHMP) backed approval of Bexsero, the Swiss drug giant's ($NVS) meningitis B vaccine that could become the first such shot to hit the market if the European Commission follows the CHMP's advice.

Novartis vaccines get booster shot with EMA nod for Bexsero

Novartis' struggling vaccine unit got a shot in the arm today when the European Medicines Agency (EMA) recommended for approval, Bexsero, its potential blockbuster vaccine for meningitis B.

Meningitis vaccine ruled safe for warm storage

The World Health Organization deemed an inexpensive meningitis vaccine safe out of cold storage for four days, meaning health workers can more easily transport the drug to remote parts of Africa where meningitis A is common.

FDA Commish asks for more power over compounding

As FDA Commissioner Margaret Hamburg prepared to testify before Congress about the deadly meningitis outbreak, reports surfaced that the agency wanted to shut New England Compounding Center down to fix manufacturing violations in 2003, but deferred to state regulators who apparently dropped the ball.

CDC green-lights GSK's meningitis vaccine for at-risk infants

A Centers for Disease Control and Prevention panel recommended the use of GlaxoSmithKline's MenHibrix vaccine for bacterial meningitis for use in babies at increased risk of infection.

Outbreak probe broadens as first patient sues compounding pharmacy

As a Minnesota woman became the first patient to sue New England Compounding over the meningitis outbreak suspected to have originated there, the company hired a prominent criminal-defense firm, and federal and state authorities stepped up their probes.

Another compounding group shuts amid outbreak

As the meningitis outbreak spreads, so does the fallout from it. A second company in Massachusetts is suspending operations, The Boston Globe reports, while officials investigate. Meanwhile, calls for tougher oversight of pharmaceutical compounding are, predictably, intensifying.

FDA green-lights GSK's MenHibrix

The vaccine targets infections with Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type B, and is given as four doses between 6 weeks and 18 months of age. Both of these infections can cause meningitis.